ONENESS

Oneness is currently actively developing several indications other than DFU, including skin ulcers after radiation therapy, venous leg ulcers, scars, biomembrane wounds, and bedsores. Each is a skin lesion that is refractory or doesn't have a better treatment... Oneness is committed to the development of new drug for the global unmet medical needs. With the global vision in innovation, we screen new drugs and initiate an in-depth exploration into the drug mechanism and pathology. The in-house research and development technology has been established to compete with international pharmaceutical companies and to maximize the value by our science and innovation... Oneness Biotech was established in June 2008 and has been approved as a "New Drug Biotech" company by the government. In June 2011, Oneness received approval from Securities and Futures Bureau (FSC) to be listed on the stock market and started to be traded since September 23rd 2011 (ticker: 4743). Oneness acquired Fountain..